Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Yield10 Bioscience Inc (NASDAQ: YTEN) closed the day trading at $0.23 down -8.75% from the previous closing price of $0.26. In other words, the price has decreased by -$8.75 from its previous closing price. On the day, 1.09 million shares were traded. YTEN stock price reached its highest trading level at $0.26 during the session, while it also had its lowest trading level at $0.2131.
Ratios:
For a better understanding of YTEN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.29 and its Current Ratio is at 0.29.
On September 10, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.
National Securities Upgraded its Neutral to Buy on August 27, 2020, while the target price for the stock was maintained at $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’23 when SCHULER JACK W sold 36,000 shares for $0.21 per share. The transaction valued at 7,430 led to the insider holds 1,566,956 shares of the business.
SCHULER JACK W sold 35,000 shares of YTEN for $8,320 on Dec 08 ’23. The 10% Owner now owns 1,602,956 shares after completing the transaction at $0.24 per share. On Oct 06 ’23, another insider, SCHULER JACK W, who serves as the 10% Owner of the company, sold 37,931 shares for $0.30 each. As a result, the insider received 11,448 and left with 872,956 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YTEN now has a Market Capitalization of 3611698 and an Enterprise Value of 5721700. For the stock, the TTM Price-to-Sale (P/S) ratio is 60.19. Its current Enterprise Value per Revenue stands at 95.362 whereas that against EBITDA is -0.405.
Stock Price History:
The Beta on a monthly basis for YTEN is 1.67, which has changed by -0.9198606 over the last 52 weeks, in comparison to a change of 0.22640884 over the same period for the S&P500. Over the past 52 weeks, YTEN has reached a high of $3.29, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -19.05%, while the 200-Day Moving Average is calculated to be -51.43%.
Shares Statistics:
Over the past 3-months, YTEN traded about 5.04M shares per day on average, while over the past 10 days, YTEN traded about 438590 shares per day. A total of 15.40M shares are outstanding, with a floating share count of 12.41M. Insiders hold about 19.42% of the company’s shares, while institutions hold 3.94% stake in the company. Shares short for YTEN as of 1711584000 were 940871 with a Short Ratio of 0.19, compared to 1709164800 on 290525. Therefore, it implies a Short% of Shares Outstanding of 940871 and a Short% of Float of 6.3100000000000005.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Yield10 Bioscience Inc (YTEN) in the stock market.On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.13, while EPS last year was -$0.76. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.15 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.62 and -$0.89 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.85, with 1.0 analysts recommending between -$0.85 and -$0.85.
Revenue Estimates
2 analysts predict $1.87M in revenue for the current quarter. It ranges from a high estimate of $2.25M to a low estimate of $1.5M. As of the current estimate, Yield10 Bioscience Inc’s year-ago sales were $60k
A total of 2 analysts have provided revenue estimates for YTEN’s current fiscal year. The highest revenue estimate was $3M, while the lowest revenue estimate was $1.5M, resulting in an average revenue estimate of $2.25M. In the same quarter a year ago, actual revenue was $60kBased on 1 analysts’ estimates, the company’s revenue will be $4M in the next fiscal year. The high estimate is $4M and the low estimate is $4M.
